MARKET

IDXG

IDXG

Interpace Biosciences Inc
OTCID
6.00
NaN%
Closed 09:30 10/05 EDT
OPEN
--
PREV CLOSE
6.39
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
11.90
52 WEEK LOW
3.850
MARKET CAP
33.24M
P/E (TTM)
1.360
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IDXG last week (0928-1002)?
Weekly Report · 23h ago
Weekly Report: what happened at IDXG last week (0921-0925)?
Weekly Report · 09/28 10:03
U.S. IPO Weekly Recap: Postponed Deals Put Damper On Fall IPO Market
Seeking Alpha · 09/26 02:40
Weekly Report: what happened at IDXGD last week (0914-0918)?
Weekly Report · 09/21 10:03
Weekly Report: what happened at IDXGD last week (0907-0911)?
Weekly Report · 09/14 10:07
Weekly Report: what happened at IDXGD last week (0831-0904)?
Weekly Report · 09/07 10:02
Weekly Report: what happened at IDXGD last week (0824-0828)?
Weekly Report · 08/31 10:08
Interpace Biosciences announces 1-for-5 reverse split for Nasdaq uplisting
TipRanks · 08/26 20:50
More
About IDXG
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.

Webull offers Interpace Biosciences Inc stock information, including OTCID: IDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDXG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IDXG stock methods without spending real money on the virtual paper trading platform.